 | • レポートコード：MRC2-11QY13670 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はアルツハイマー病治療薬のグローバル市場について調査・分析したレポートです。種類別（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬）市場規模、用途別（病院、診療所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別アルツハイマー病治療薬の競争状況、市場シェア ・世界のアルツハイマー病治療薬市場：種類別市場規模 2015年-2020年（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬） ・世界のアルツハイマー病治療薬市場：種類別市場規模予測 2021年-2026年（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬） ・世界のアルツハイマー病治療薬市場：用途別市場規模 2015年-2020年（病院、診療所） ・世界のアルツハイマー病治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所） ・北米のアルツハイマー病治療薬市場分析：米国、カナダ ・ヨーロッパのアルツハイマー病治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのアルツハイマー病治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のアルツハイマー病治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのアルツハイマー病治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：F. Hoffmann-La Roche、Merck、Pfizer、Novartis、Eisai、Actavis、Daiichi Sankyo ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer’s disease may lead to death. According to National Institute of Aging, Alzheimer’s disease is the common form of dementia.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
Market Analysis and Insights: Global Alzheimers Disease Therapeutics Market
The global Alzheimers Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Alzheimers Disease Therapeutics Scope and Market Size
Alzheimers Disease Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimers Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
F. Hoffmann-La Roche
Merck
Pfizer
Novartis
Eisai
Actavis
Daiichi Sankyo
…
Market segment by Type, the product can be split into
Biomarkers
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Market segment by Application, split into
Hospitals
Clinics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alzheimers Disease Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Alzheimers Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Biomarkers
1.4.3 Cholinesterase Inhibitors
1.4.4 NMDA Receptor Antagonists
1.5 Market by Application
1.5.1 Global Alzheimers Disease Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Alzheimers Disease Therapeutics Market Perspective (2015-2026)
2.2 Global Alzheimers Disease Therapeutics Growth Trends by Regions
2.2.1 Alzheimers Disease Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alzheimers Disease Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Alzheimers Disease Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Alzheimers Disease Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Alzheimers Disease Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Alzheimers Disease Therapeutics Players by Market Size
3.1.1 Global Top Alzheimers Disease Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Alzheimers Disease Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Alzheimers Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alzheimers Disease Therapeutics Market Concentration Ratio
3.2.1 Global Alzheimers Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alzheimers Disease Therapeutics Revenue in 2019
3.3 Alzheimers Disease Therapeutics Key Players Head office and Area Served
3.4 Key Players Alzheimers Disease Therapeutics Product Solution and Service
3.5 Date of Enter into Alzheimers Disease Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Alzheimers Disease Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Alzheimers Disease Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
5.2 Global Alzheimers Disease Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Alzheimers Disease Therapeutics Market Size (2015-2020)
6.2 Alzheimers Disease Therapeutics Key Players in North America (2019-2020)
6.3 North America Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
6.4 North America Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Alzheimers Disease Therapeutics Market Size (2015-2020)
7.2 Alzheimers Disease Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
7.4 Europe Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Alzheimers Disease Therapeutics Market Size (2015-2020)
8.2 Alzheimers Disease Therapeutics Key Players in China (2019-2020)
8.3 China Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
8.4 China Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Alzheimers Disease Therapeutics Market Size (2015-2020)
9.2 Alzheimers Disease Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
9.4 Japan Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Alzheimers Disease Therapeutics Market Size (2015-2020)
10.2 Alzheimers Disease Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Alzheimers Disease Therapeutics Market Size (2015-2020)
11.2 Alzheimers Disease Therapeutics Key Players in India (2019-2020)
11.3 India Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
11.4 India Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Alzheimers Disease Therapeutics Market Size (2015-2020)
12.2 Alzheimers Disease Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Alzheimers Disease Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Alzheimers Disease Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 F. Hoffmann-La Roche
13.1.1 F. Hoffmann-La Roche Company Details
13.1.2 F. Hoffmann-La Roche Business Overview
13.1.3 F. Hoffmann-La Roche Alzheimers Disease Therapeutics Introduction
13.1.4 F. Hoffmann-La Roche Revenue in Alzheimers Disease Therapeutics Business (2015-2020))
13.1.5 F. Hoffmann-La Roche Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Alzheimers Disease Therapeutics Introduction
13.2.4 Merck Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Alzheimers Disease Therapeutics Introduction
13.3.4 Pfizer Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Alzheimers Disease Therapeutics Introduction
13.4.4 Novartis Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Eisai
13.5.1 Eisai Company Details
13.5.2 Eisai Business Overview
13.5.3 Eisai Alzheimers Disease Therapeutics Introduction
13.5.4 Eisai Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.5.5 Eisai Recent Development
13.6 Actavis
13.6.1 Actavis Company Details
13.6.2 Actavis Business Overview
13.6.3 Actavis Alzheimers Disease Therapeutics Introduction
13.6.4 Actavis Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.6.5 Actavis Recent Development
13.7 Daiichi Sankyo
13.7.1 Daiichi Sankyo Company Details
13.7.2 Daiichi Sankyo Business Overview
13.7.3 Daiichi Sankyo Alzheimers Disease Therapeutics Introduction
13.7.4 Daiichi Sankyo Revenue in Alzheimers Disease Therapeutics Business (2015-2020)
13.7.5 Daiichi Sankyo Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Alzheimers Disease Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Alzheimers Disease Therapeutics Revenue
Table 3. Ranking of Global Top Alzheimers Disease Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alzheimers Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Biomarkers
Table 6. Key Players of Cholinesterase Inhibitors
Table 7. Key Players of NMDA Receptor Antagonists
Table 8. Global Alzheimers Disease Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Alzheimers Disease Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Alzheimers Disease Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Alzheimers Disease Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Alzheimers Disease Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Alzheimers Disease Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Alzheimers Disease Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Alzheimers Disease Therapeutics Players
Table 19. Global Alzheimers Disease Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Alzheimers Disease Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Alzheimers Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimers Disease Therapeutics as of 2019)
Table 22. Global Alzheimers Disease Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Alzheimers Disease Therapeutics Product Solution and Service
Table 25. Date of Enter into Alzheimers Disease Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Alzheimers Disease Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Alzheimers Disease Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Alzheimers Disease Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Alzheimers Disease Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 35. North America Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 37. North America Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 41. Europe Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 47. China Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 49. China Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 53. Japan Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 65. India Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 67. India Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Alzheimers Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Alzheimers Disease Therapeutics Market Share (2019-2020)
Table 71. Central & South America Alzheimers Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Alzheimers Disease Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Alzheimers Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Alzheimers Disease Therapeutics Market Share by Application (2015-2020)
Table 75. F. Hoffmann-La Roche Company Details
Table 76. F. Hoffmann-La Roche Business Overview
Table 77. F. Hoffmann-La Roche Product
Table 78. F. Hoffmann-La Roche Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 79. F. Hoffmann-La Roche Recent Development
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Product
Table 83. Merck Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 84. Merck Recent Development
Table 85. Pfizer Company Details
Table 86. Pfizer Business Overview
Table 87. Pfizer Product
Table 88. Pfizer Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 89. Pfizer Recent Development
Table 90. Novartis Company Details
Table 91. Novartis Business Overview
Table 92. Novartis Product
Table 93. Novartis Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 94. Novartis Recent Development
Table 95. Eisai Company Details
Table 96. Eisai Business Overview
Table 97. Eisai Product
Table 98. Eisai Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 99. Eisai Recent Development
Table 100. Actavis Company Details
Table 101. Actavis Business Overview
Table 102. Actavis Product
Table 103. Actavis Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 104. Actavis Recent Development
Table 105. Daiichi Sankyo Company Details
Table 106. Daiichi Sankyo Business Overview
Table 107. Daiichi Sankyo Product
Table 108. Daiichi Sankyo Revenue in Alzheimers Disease Therapeutics Business (2015-2020) (Million US$)
Table 109. Daiichi Sankyo Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alzheimers Disease Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Biomarkers Features
Figure 3. Cholinesterase Inhibitors Features
Figure 4. NMDA Receptor Antagonists Features
Figure 5. Global Alzheimers Disease Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Alzheimers Disease Therapeutics Report Years Considered
Figure 9. Global Alzheimers Disease Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Alzheimers Disease Therapeutics Market Share by Regions: 2020 VS 2026
Figure 11. Global Alzheimers Disease Therapeutics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Alzheimers Disease Therapeutics Market Share by Players in 2019
Figure 14. Global Top Alzheimers Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimers Disease Therapeutics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Alzheimers Disease Therapeutics Revenue in 2019
Figure 16. North America Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Alzheimers Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
胃食道逆流症（GERD）治療薬の世界市場（～2026年） Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications. Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attrib…- 獣医感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Veterinary Infectious Disease Therapeutics Market The global Veterinary Infectious Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Veterinary Infectious Disease…
- 冠動脈疾患治療薬の世界市場（～2026年） Coronary artery disease (CAD), also known as ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. Our research analysis on the global coronary artery disease therapeutics market has identified that…
- 非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …
- フォンウィルブランド病（VWD）治療薬の世界市場（～2026年） Von Willebrand Disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand Factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the cir…